Facioscapulohumeral Dystrophy clinical trials at University of California Health

1 in progress, 0 open to eligible people

Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
Sorry, not currently recruiting here
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
at UC Irvine

Our lead scientists for Facioscapulohumeral Dystrophy research studies include Namita Goyal.

Last updated: July 24, 2026

Del-brax (Also Referred to as AOC 1020) in Participants With FSHD